Next Article in Journal
Recommendations for the Referral of Patients for Proton-Beam Therapy, an Alberta Health Services Report: A Model for Canada?
Previous Article in Journal
Implementing a Regional Oncology Information System: Approach and Lessons Learned
 
 
Current Oncology is published by MDPI from Volume 28 Issue 1 (2021). Previous articles were published by another publisher in Open Access under a CC-BY (or CC-BY-NC-ND) licence, and they are hosted by MDPI on mdpi.com as a courtesy and upon agreement with Multimed Inc..
Font Type:
Arial Georgia Verdana
Font Size:
Aa Aa Aa
Line Spacing:
Column Width:
Background:
Article

A Canadian Consensus on the Management of Newly Diagnosed and Relapsed Acute Promyelocytic Leukemia in Adults

1
Princess Margaret Hospital, Toronto, ON, Canada
2
University of British Columbia, Vancouver, BC, Canada
3
Dalhousie University, Halifax, NS, Canada
4
McMaster University, Hamilton, ON, Canada
5
McGill University Health Centre, Montreal, QC, Canada
6
New Evidence, Toronto, ON, Canada
*
Author to whom correspondence should be addressed.
Curr. Oncol. 2014, 21(5), 234-250; https://doi.org/10.3747/co.21.2183
Submission received: 3 July 2014 / Revised: 7 August 2014 / Accepted: 10 September 2014 / Published: 1 October 2014

Abstract

The use of all-trans-retinoic acid (ATRA) and anthracyclines (with or without cytarabine) in the treatment of acute promyelocytic leukemia (APL) has dramatically changed the management and outcome of the disease over the past few decades. The addition of arsenic trioxide (ATO) in the relapsed setting—and, more recently, in reduced-chemotherapy or chemotherapy-free approaches in the first-line setting—continues to improve treatment outcomes by reducing some of the toxicities associated with anthracycline-based approaches. Despite those successes, a high rate of early death from complications of coagulopathy remains the primary cause of treatment failure before treatment begins. In addition to that pressing issue, clarity is needed about the use of ATO in the first-line setting and the role of hematopoietic stem-cell transplantation (HSCT) in the relapsed setting. The aim for the present consensus was to provide guidance to health care professionals about strategies to reduce the early death rate, information on the indications for HSCT and on the use of ATO in induction and consolidation in low-to-intermediate–risk and high-risk APL patients.
Keywords: acute promyelocytic leukemia; apl; management; supportive care; prophylaxis; infusions; arsenic trioxide; ato; Trisenox; first-line treatment; transplantation; allogeneic transplantation; autologous transplantation acute promyelocytic leukemia; apl; management; supportive care; prophylaxis; infusions; arsenic trioxide; ato; Trisenox; first-line treatment; transplantation; allogeneic transplantation; autologous transplantation

Share and Cite

MDPI and ACS Style

Seftel, M.D.; Barnett, M.J.; Couban, S.; Leber, B.; Storring, J.; Assaily, W.; Fuerth, B.; Christofides, A.; Schuh, A.C. A Canadian Consensus on the Management of Newly Diagnosed and Relapsed Acute Promyelocytic Leukemia in Adults. Curr. Oncol. 2014, 21, 234-250. https://doi.org/10.3747/co.21.2183

AMA Style

Seftel MD, Barnett MJ, Couban S, Leber B, Storring J, Assaily W, Fuerth B, Christofides A, Schuh AC. A Canadian Consensus on the Management of Newly Diagnosed and Relapsed Acute Promyelocytic Leukemia in Adults. Current Oncology. 2014; 21(5):234-250. https://doi.org/10.3747/co.21.2183

Chicago/Turabian Style

Seftel, M.D., M.J. Barnett, S. Couban, B. Leber, J. Storring, W. Assaily, B. Fuerth, A. Christofides, and A.C. Schuh. 2014. "A Canadian Consensus on the Management of Newly Diagnosed and Relapsed Acute Promyelocytic Leukemia in Adults" Current Oncology 21, no. 5: 234-250. https://doi.org/10.3747/co.21.2183

Article Metrics

Back to TopTop